Jpmorgan Chase & CO Medicinova Inc Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Medicinova Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,376 shares of MNOV stock, worth $9,031. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,376

Previous 33,476 83.94%

Holding current value

$9,031

Previous $48,000 85.42%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.28 - $1.57 $35,968 - $44,117	-28,100 Reduced 83.94%	5,376 $7,000
Q1 2024 May 10, 2024	SELL	$1.28 - $1.65 $127,944 - $164,929	-99,957 Reduced 74.91%	33,476 $48,000
Q4 2023 Feb 12, 2024	SELL	$1.38 - $2.06 $2,681 - $4,002	-1,943 Reduced 1.44%	133,433 $200,000
Q3 2023 Nov 14, 2023	SELL	$2.01 - $2.6 $66,000 - $85,373	-32,836 Reduced 19.52%	135,376 $282,000
Q2 2023 Aug 11, 2023	SELL	$2.09 - $2.43 $17,062 - $19,838	-8,164 Reduced 4.63%	168,212 $386,000
Q1 2023 May 11, 2023	SELL	$1.95 - $2.54 $142,289 - $185,341	-72,969 Reduced 29.26%	176,376 $380,000
Q4 2022 Feb 13, 2023	SELL	$1.97 - $2.66 $96,000 - $129,624	-48,731 Reduced 16.35%	249,345 $511,000
Q3 2022 Nov 14, 2022	BUY	$2.1 - $2.6 $5,670 - $7,020	2,700 Added 0.91%	298,076 $647,000
Q2 2022 Aug 11, 2022	SELL	$2.31 - $3.14 $29,799 - $40,506	-12,900 Reduced 4.18%	295,376 $747,000
Q1 2022 May 11, 2022	BUY	$2.19 - $2.81 $15,570 - $19,979	7,110 Added 2.36%	308,276 $823,000
Q4 2021 Feb 10, 2022	BUY	$2.61 - $4.42 $62,694 - $106,172	24,021 Added 8.67%	301,166 $807,000
Q3 2021 Nov 12, 2021	BUY	$3.4 - $4.24 $942,293 - $1.18 Million	277,145 New	277,145 $1.05 Million

Others Institutions Holding MNOV

# of Institutions

Shares Held

4.69M

Call Options Held

7.2K

Put Options Held

3.8K

View Full List

About MEDICINOVA INC

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $82.4M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

More about MNOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Medicinova Inc Transaction History